Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Industry Calls for More Tailored Govt Support on Drug Loss Product Development
Pharmaceutical industry officials in Japan are urging the government to go beyond its current support framework for so-called “drug loss” products and provide clearer regulatory guidance and stronger incentives particularly for firms accepting open calls for development sponsors. Speaking to…
To read the full story
Related Article
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
May 21, 2025
- MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
May 12, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…